On July 16, GenScript Biotech fell 6.34% in regular trading, trading at HK$14.1/share, with turnover of HK$57.82 million.

On the news front, the company disclosed after the previous session that its associate Legend Biotech reported CARVYKTI Q2 net trade sales of approximately US$657 million for the quarter ended June 30, representing roughly 10% sequential growth from Q1's US$597 million. The quarter-over-quarter growth rate decelerated notably compared to the 62% year-over-year surge recorded in Q1. Market participants interpreted the slowdown as a signal of moderating commercial momentum.

GenScript had rallied over 5% on each of July 13 and July 15, driven by optimism around CXO sector mid-year earnings expectations, accumulating significant gains. Following the release of the Q2 sales figure — which some market commentary suggested fell short of consensus expectations — profit-taking pressure intensified, reversing the prior rally.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)